CLOTRIMADERM VAGINAL 6 CREAM

Land: Canada

Sprog: engelsk

Kilde: Health Canada

Aktiv bestanddel:

CLOTRIMAZOLE

Tilgængelig fra:

TARO PHARMACEUTICALS INC

ATC-kode:

G01AF02

INN (International Name):

CLOTRIMAZOLE

Dosering:

1%

Lægemiddelform:

CREAM

Sammensætning:

CLOTRIMAZOLE 1%

Indgivelsesvej:

VAGINAL

Enheder i pakken:

50GM

Recept type:

OTC

Terapeutisk område:

AZOLES

Produkt oversigt:

Active ingredient group (AIG) number: 0110231001; AHFS:

Autorisation status:

APPROVED

Autorisation dato:

2020-02-21

Produktets egenskaber

_PAGE 1 OF 22_
_ _
_CLOTRIMADERM VAGINAL 6 _
_CLOTRIMADERM VAGINAL 3 _
_CLOTRIMADERM EXTERNAL CREAM _
PRODUCT
MO
N
OG
RA
PH
CLOTRIMADERM VAGINAL 6
(Clotrimazo le
Vaginal Cream USP 1%)
CLOTRIMADERM VAGINAL 3
(Clotrimazo le
Vaginal Cream USP 2%)
CLOTRIMADERM EXTERNAL C
RE
AM
(Clotrimazole
Vaginal Cream USP 1%)
ANTIFUNGAL
AG
E
NT
Taro Pharmaceuticals
Inc. Date of Revision:
130 East Drive
April 29, 2022
Brampton,
Ontario
L6T 1C1
CONTROL #263252
_PAGE 2 OF 22_
_ _
_CLOTRIMADERM VAGINAL 6 _
_CLOTRIMADERM VAGINAL 3 _
_CLOTRIMADERM EXTERNAL CREAM _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................... 3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................
3
CONTRAINDICATIONS
.............................................................................................................
3
WARNINGS AND
PRECAUTIONS.............................................................................................
3
ADVERSE REACTIONS
.............................................................................................................
4
DRUG INTERACTIONS
..............................................................................................................
5
DOSAGE AND
ADMINISTRATION...........................................................................................
6
OVERDOSAGE
............................................................................................................................
6
ACTION AND CLINICAL PHARMACOLOGY
......................................................................
6
STORAGE AND
STABILITY.......................................................................................................
8
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................................. 8
PART II: SCIENTIFIC INFORMATION
....